The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
Open accessAbstract
VEGF-A drives T cell exhaustion via TOX-dependent transcriptional programming in microsatellite stable colorectal cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [60]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · cited 1×
“INTRODUCTION Tumor antigen–specific T cells within the tumor microenvironment are exhausted, and their antitumor functions are substantially impaired (1, 2).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Cited by
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Self-citationTumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity
Park, J., Hsueh, P.-C., Li, Z., & Ho, P.-C. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.008 · Cited by 371
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
“Recent data from a series of in vitro, in vivo, and ex vivo studies demonstrated that severe T-cell exhaustion driven by VEGF-A was highly prominent in MSS CRC tumors compared with MSI-H CRC tumors (54).”
ResultZhao, Y., Guo, S., Deng, J., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70958 · Cited by 246
“resistance, combined blockade of PD-1 and VEGF-A activities restores the anti-tumor function of T cells, resulting in better tumor control [51] (Figure 2A).”
BackgroundLiu, C., Liu, R., Wang, B., Lian, J., Yao, Y., Sun, H., Zhang, C., Fang, L., Guan, X., Shi, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001895 · Cited by 257
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy-Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 184
“In mouse tumor models, VEGF-A/VEGFR-2 and PD-1 blockade induces strong and synergic antitumor responses and limits T-cell exhaustion in VEGF-A-expressing tumor compared to monotherapies in mouse models of MSS colorectal cancer (44, 50).”
BackgroundResultHyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Kim, C. G., Kim, C., Yoon, S. E., Kim, K. H., Choi, S. J., Kang, B., Kim, H. R., Park, S.-H., Shin, E.-C., Kim, Y.-Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.010 · Cited by 185
Self-citationLee, J. B., Kim, H. R., & Ha, S.-J. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 174
“In 2019, TOX, a master transcription factor that transcriptionally and independently programs T cell exhaustion, was identified (112-117).”
BackgroundSelf-citationPD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 178
Kumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 183
Kim, K., Park, S., Park, S. Y., Kim, G., Park, S. M., Cho, J.-W., Kim, D. H., Park, Y. M., Koh, Y. W., Kim, H. R., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00722-9 · Cited by 158
“A series of recent studies reported that TOX promotes CD8 T-cell exhaustion in chronic viral infection and cancer [30-32, 44-47].”
BackgroundSelf-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Saka, D., Gökalp, M., Piyade, B., Çevik, N. C., Sever, E. A., Unutmaz, D., Ceyhan, G. O., Demir, İ. E., & Asimgil, H. (2020) · Cancers · doi:10.3390/cancers12082274 · Cited by 174
Hsu, C., Ou, D., Bai, L., Chen, C., Lin, L., Huang, S.-F. K., Cheng, A., Jeng, Y., & Hsu, C. (2021) · Liver Cancer · doi:10.1159/000515305 · Cited by 160
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang, Y., & Brekken, R. A. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0222-082r · Cited by 155
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 152
“…of pro-apoptotic effectors in vascular endothelial cells 30 , endothelial cell anergy and reactivation of an embryonic vessel-like barrier phenotype 29,30 , all involve changes induced in endothelial cells from angiogenic tumour blood vessels (for example, when VEGF binds to VEGFR2, to stimulate…”
Xiong, Z., Chan, S. L., Zhou, J., Vong, J. S. L., Kwong, T. T., Zeng, X., Wu, H., Cao, J., Tu, Y., Feng, Y., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328364 · Cited by 131
Recent Advances in Immunotherapy for Hepatocellular Carcinoma
Nakano, S., Eso, Y., Okada, H., Takai, A., Takahashi, K., & Seno, H. (2020) · Cancers · doi:10.3390/cancers12040775 · Cited by 117
“In addition, a recent study demonstrated that anti-VEGF therapy rescues effector T cells from exhaustion by downregulating the transcription factor TOX [46].”
BackgroundWang, Q., Gao, J., Di, W. J., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02576-x · Cited by 107
Bao, X., Zhang, H., Wu, W., Cheng, S., Dai, X., Zhu, X., Fu, Q., Tong, Z., Liu, L., Zheng, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001437 · Cited by 114
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 97
Ge, Z., Zhou, G., Carrascosa, L. C., Gausvik, E., Boor, P. P. C., Noordam, L., Doukas, M., Polak, W. G., Terkivatan, T., Pan, Q., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.03.003 · Cited by 96
“RESULTS: TIGIT was enriched, whereas its co-stimulatory counterpart CD226was down-regulated onPD1high CD8þ TILs.”
BackgroundInfluentialLinking tumour angiogenesis and tumour immunity
Kabir, A. U., Subramanian, M., Kwon, Y., & Choi, K. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01211-z · Cited by 110
“Indeed, preclinical studies have shown that combining ICB with anti-angiogenic treatments can improve tumour outcomes in models of pancreatic, mammary, renal, lung, melanoma, ovarian, hepatocellular and colorectal carcinomas 121,123,124,127,145,158–164 .”
Yang, Z., Gao, J., Zheng, J., Han, J., Li, A., Liu, G., Sun, Y., Zhang, J., Chen, G., Xu, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01762-y · Cited by 96
Self-citationImmunosuppressive effects of vascular endothelial growth factor (Review)
Ribatti, D. (2022) · Oncology Letters · doi:10.3892/ol.2022.13489 · Cited by 100
“Moreover, VEGFA contributes to CD8+ T‐cell exhaustion, which is characterized via the expression of negative immune checkpoints, such as programmed cell death protein‐1 (PD‐1) receptors (17), in a VEGFR‐2 and nuclear factor of activated T‐cells‐dependent manner.”
BackgroundMechanism and strategies of immunotherapy resistance in colorectal cancer
Shan, J., Han, D. H., Shen, C., Lei, Q., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016646 · Cited by 97
“For example, a clinical trial (NCT04126733) Frontiers in Immunology 10 that began in 2019 focused on the efficacy of regorafenib, a VEGFR inhibitor targeting TME angiogenesis, in combination with nivolumab in patients with pMMR-MSS CRC.”
BackgroundHan, H. S., Jeong, S., Kim, H., Kim, H., Kim, A. R., Kwon, M., Park, S., Woo, C. G., Kim, H. K., Lee, K. H., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.035 · Cited by 85
Self-citationPortal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…
Allaire, M., Rudler, M., & Thabut, D. (2021) · Liver International · doi:10.1111/liv.14977 · Cited by 90
Epigenetic strategies to boost CAR T cell therapy
Akbari, B., Ghahri-Saremi, N., Soltantoyeh, T., Hadjati, J., Ghassemi, S., & Mirzaei, H. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.003 · Cited by 82
Xie, P., Yu, M., Zhang, B., Yu, Q., Zhao, Y., Wu, M., Lei, J., Yan, J., Zhou, B., Liu, S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.02.009 · Cited by 88
Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer
Tu, V. Y., Ayari, A., & O’Connor, R. S. (2021) · Antibodies · doi:10.3390/antib10030025 · Cited by 85
“The nature and consequence of histone posttranslational modifications are highly specific: H3K27 acetylation within intronic regions is a hallmark of exhausted T cells [24]; higher levels of acetylation at the IFN-γ promoter distinguish memory and effector T cells from their naïve counterparts [25].”
BackgroundCombining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
Self-citationMilestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 87
“Accordingly, genetic inactivation of Vegfr2 in T cells relieved T cell exhaustion in a colorectal cancer model 269 .”
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“associated HMG-bOX (TOX)-mediated depletion of cytotoxic T lymphocytes (CTLs) [19].”
BackgroundGallic acid induces T-helper-1-like T reg cells and strengthens immune checkpoint blockade efficacy
Deng, B., Yang, B., Chen, J., Wang, S., Zhang, W., Guo, Y., Han, Y., Li, H., Dang, Y., Yuan, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004037 · Cited by 83
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 82
“Indeed, VEGFA can induce the activation of the master regulator of T cell exhaustion, TOX, as well as the expression of the PD-1 checkpoint in tumor-reactive, CD8+ T cells (Kim et al., 2019).”
BackgroundInfluentialDynamic chromatin regulatory landscape of human CAR T cell exhaustion
Gennert, D. G., Lynn, R. C., Granja, J. M., Weber, E. W., Mumbach, M. R., Zhao, Y., Duren, Z., Sotillo, E., Greenleaf, W. J., Wong, W. H., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104758118 · Cited by 74
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 75
Li, S., Na, R., Li, X., Zhang, Y., & Zheng, T. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188758 · Cited by 74
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function
Yü, P., Shan, J., Liu, Y., Liu, F., Wang, L., Liu, Z., Li, J., Yue, D., Wang, L., Chen, X., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03308-z · Cited by 68
Targeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 76
VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
Zhang, Y., Huang, H., Coleman, M., Žiemys, A., Gopal, P., Kazmi, S. M. A., & Brekken, R. A. (2021) · JCI Insight · doi:10.1172/jci.insight.150735 · Cited by 66
“These observations have been expanded by recent studies that have shown VEGF-induced, T cell exhaustion–specific transcriptional programs are dependent on TOX in microsatellite stable colorectal cancers (37).”
ResultWang, L., Zhang, L., Zhao, L., Shao, S. H., Ning, Q., Jing, X., Zhang, Y., Fengyu, Z., Liu, X., Gu, S., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86085 · Cited by 65
“Recent studies suggest that VEGFA/NRP-1 acts as an important effector in regulating the CSC phenotype and TME [23, 33].”
BackgroundThe therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Liu, Z., Lu, T., Li, J., Wang, L., Xu, K., Dang, Q., Liu, L., Guo, C., Jiao, D., Sun, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702594 · Cited by 74
“For example, VEGFA induces the expression of transcription factor TOX to drive T cell exhaustion (43), and the expression of CASP1 is able to be repressed by G9A and further promotes tumor immune escape (44).”
BackgroundThe tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 65
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 62
“TOX is activated by vascular endothelial growth factor (VEGF)-A upon binding to VEGF receptor (VEGFR) on T cells and inhibition of VEGFR potentiated anti-tumor immunity in mice treated with ICI [63].”
BackgroundRe-defining T-Cell Exhaustion: Subset, Function, and Regulation
Im, S. J., & Ha, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e2 · Cited by 60
“In addition, knockdown of Tox in human CD8 TILs led to an increased production of effector cytokines and an enhanced cytotoxicity in vitro (97).”
BackgroundTumors resurrect an embryonic vascular program to escape immunity
Huijbers, E. J. M., Khan, K. A., Kerbel, R. S., & Griffioen, A. W. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm6388 · Cited by 64
Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment
Guan, Q., Han, M., Guo, Q., Yan, F., Wang, M., Ning, Q., & Xi, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204363 · Cited by 59
“Anti-VEGFA antibody decreased expression of inhibitory receptors (PD1, TIM3, LAG3, TIGIT), and increased IFN-g and TNF production in CD8 TEXs (59).”
BackgroundKnowns and Unknowns about CAR-T Cell Dysfunction
Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14041078 · Cited by 59
Kim, H. S., Kim, C. G., Kim, W. K., Kim, K., Yoo, J., Min, B. S., Paik, S., Shin, S. J., Lee, H., Lee, K., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1101291 · Cited by 59
Self-citationKim, C. G., Kim, G., Kim, K. H., Park, S., Shin, S., Yeo, D., Shim, H. S., Yoon, H. I., Park, S. Y., Ha, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002780 · Cited by 61
Self-citationOvercoming cancer therapy resistance: From drug innovation to therapeutics
Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 59
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
“By combining VEGF-targeted therapies and anti-PD-1, improved anti-tumor immune response was achieved (121, 122).”
BackgroundInfluentialZheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., Wang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035323 · Cited by 53
Kim, H., Jeong, S., Park, S., Lee, Y. J., Ju, Y. S., Kim, D., Song, G., Lee, J. H., Kim, S., Shin, J., et al. (2021) · Liver International · doi:10.1111/liv.14814 · Cited by 48
Self-citationT cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 53
Inflammatory signals are sufficient to elicit TOX expression in mouse and human CD8+ T cells
Maurice, N. J., Berner, J., Taber, A. K., Zehn, D., & Prlic, M. (2021) · JCI Insight · doi:10.1172/jci.insight.150744 · Cited by 49
He, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 48
“The combination of a PD-1 inhibitor and VEGF-a inhibitor effectively restores the antitumor function of T cells in MSS CRC, achieving a better therapeutic effect (76).”
BackgroundChen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
Self-citationKim, C. G., Hong, M. H., Kim, K. H., Seo, I., Ahn, B., Pyo, K., Synn, C., Yoon, H. I., Shim, H. S., Lee, Y. I., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.028 · Cited by 49
Self-citationCurrent Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
Zhang, Y., Cui, Q., Xu, M., Liu, D., Yao, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901772 · Cited by 51
Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer
Ding, J., Yang, K., Zhou, H., Huang, Y.-F., Li, H., & Zong, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149622 · Cited by 50
Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis
Sfera, A., Osorio, C., Jafri, N., Diaz, E. L., & Maldonado, J. E. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01472 · Cited by 45
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 41
Self-citationHan, J. W., & Yoon, S. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091387 · Cited by 42
Self-citationTumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity
Tzeng, H., & Huang, Y.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054422 · Cited by 38
“DC101 (anti-VEGFR2 mAb) VEGFR2 colorectal cancer • Restores anti-tumor activity of T cells by combining with anti-PD-1 mAb • TAMs ↓ • Tumor control ↑ [115]”
BackgroundEffects of Cryopreservation and Thawing on Single-Cell Transcriptomes of Human T Cells
Lee, J. S., Yi, K., Ju, Y. S., & Shin, E. (2020) · Immune Network · doi:10.4110/in.2020.20.e34 · Cited by 38
“In translational research using specimens originating from a defined cohort with human subjects, the cryopreservation and thawing process is inevitable in conducting a large-scale and simultaneous experiment (3,4).”
BackgroundSelf-citationFedoriw, A., Shi, L., O’Brien, S. W., Smitheman, K. N., Wang, Y., Hou, J., Sherk, C. S., Rajapurkar, S., Laraio, J., Williams, L. J., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0614 · Cited by 42
Immunotherapeutic Potential of T Memory Stem Cells
Li, Y., Wu, D., Yang, X., & Zhou, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.723888 · Cited by 38
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
Li, J., Peng, G., Zhu, K., Jie, X., Xu, Y., Rao, X., Xu, Y., Chen, Y., Xing, B., Wu, G., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03282-6 · Cited by 39
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
Jain, S., Chalif, E. J., & Aghi, M. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.812916 · Cited by 38
“Data from colorectal cancer reveals that VEGF induces the expression of transcription factor TOX in T cells to drive an exhaustion-specific transcription program (105).”
BackgroundWang, X., Zhou, T., Chen, X., Wang, Y., Ding, Y., Tu, H., Gao, S., Wang, H., Tang, X., & Yang, Y. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004414 · Cited by 38
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
“VEGF signaling leads to accumulation of inhibitory immune cell populations within tumors, promotes T cell exhaustion [261], impairs maturation of DCs [262], and produces abnormal, tortuous, and leaky blood vessels which suppress infiltration by effector leukocytes in part by reducing expression of endothelial cell sur…”
Background(Im)maturity in Tumor Ecosystem
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.813897 · Cited by 38
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
Failla, C. M., Carbone, M. L., Ramondino, C., Bruni, E., & Orecchia, A. (2024) · Biomedicines · doi:10.3390/biomedicines13010006 · Cited by 38
Regulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells
Ebeling, S., Kowalczyk, A., Pérez-Vázquez, D., & Mattiola, I. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1171794 · Cited by 38
Yang, C., Cao, F., Huang, S., & Zheng, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717505 · Cited by 36
“It is reported that suppressive TME and T cell exhaustion are critical to for the efficacy of immunotherapy, particularly immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell therapy (39, 40).”
BackgroundYuan, M., Zhu, Z., Mao, W., Wang, H., Qian, H., Wu, J., Guo, X., & Xu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683502 · Cited by 33
“VEGF also induces the TOX-mediated exhaustion program in CD8+ CTLs (45).”
BackgroundTOX regulates T lymphocytes differentiation and its function in tumor
Niu, H., & Wang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.990419 · Cited by 34
“TOX exhausts CD8T lymphocytes in mouse models (infection (13–15) or tumor models) or human cancers, including melanoma, non-small cell lung carcinoma (16), colorectal cancer (17), liver cancer (18), bladder cancer, oral squamous cell carcinoma (19), acute myeloid leukemia (18, 20), multiple myeloma (21), and nonHodgki…”
BackgroundPeripheral helper T cells, mavericks of peripheral immune responses
Yoshitomi, H. (2023) · International Immunology · doi:10.1093/intimm/dxad041 · Cited by 35
“2), which are known to be expressed by exhausted cytotoxic CD8 T lymphocytes (CTLs) and may be involved in the expression of checkpoint molecules such as PD-1, CTLA-4, and TIGIT as well as CTLs (39, 59).”
BackgroundYou, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 36
“Kim et al reported that VEGF-A could induce transcription factor TOX expression in T cells to drive exhaustion‐specific transcription program, accounting for the resistance to PD-1 blockade in microsatellite-stable colorectal cancer (94).”
BackgroundImmunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging
Nagai, N., Kudo, Y., Aki, D., Nakagawa, H., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052238 · Cited by 32
“VEGF also causes immune suppression by inhibiting the maturation of DCs from progenitors [32], attracting MDSCs in the bone marrow to the periphery [33,34], inhibiting cytotoxic CD8+ T cells by inducing the expression of TOX, and upregulating production of PD-1 and other inhibitory checkpoints molecules [35,36].”
BackgroundXu, Z., Hao, X., Yang, K., Wang, Q., Wang, J., Lin, L., Teng, F., Li, J., & Xing, P. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03901-2 · Cited by 32
TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer
Yang, M., Huang, Q., Li, C., Jiang, Z., Sun, J. P., Wang, Z., Liang, R., Li, D., Li, B., & Zhao, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647540 · Cited by 30
“demonstrated that VEGF-A drove TOX-dependent T cell exhaustion in anti-programmed cell death 1 (PD1) resistant microsatellite stable (MSS) tumors (15).”
BackgroundWu, Q., Huang, Q., Jiang, Y., Sun, F., Liang, B., Wang, J., Hu, X., Sun, M., Ma, Z., Shi, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0124 · Cited by 33
“ICIs combined with VEGFR2 blockade has shown enhanced efficacy in MSS colorectal cancer preclinical models (4).”
BackgroundIncreased TOX expression associates with exhausted T cells in patients with multiple myeloma
Zhao, Y., Liao, P., Huang, S., Deng, T., Tan, J., Huang, Y., Zhan, H., Li, Y., Chen, S., & Zhong, L. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00267-0 · Cited by 31
“This result is consistent with the finding of up-regulation of TOX in solid tumors and lymphomas [10].”
ResultPhenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Sun, Y., Yinwang, E., Wang, S., Wang, Z., Wang, F., Xue, Y., Zhang, W., Zhao, S., Mou, H., Chen, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02104-w · Cited by 34
“These observations serve as the mechanistic under-pinning for combining anti-angiogenic agents with ICBs [194, 199, 201, 204, 207], where clinical trials have verified additive if not synergistic effects across several cancer types [208–213], which may be seen regardless of the intra-tumoural…”
BackgroundArcanjo, A. F., Pinto, K. G., Logullo, J., Leite, P. E. C., Menezes, C. C. B., Freire‐de‐Lima, L., Diniz-Lima, I., Decotè-Ricardo, D., Rodrigues‐da‐Silva, R. N., Freire-de-Lima, C. G., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab425 · Cited by 27
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 27
Role of kynurenine in promoting the generation of exhausted CD8+ T cells in colorectal cancer.
Wu, D., & Zhu, Y. (2021) · American Journal of Translational Research · Cited by 49
Huang, S., Liang, C., Zhao, Y., Deng, T., Tan, J., Zha, X., Li, Y., & Chen, S. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22049 · Cited by 26
“…TOX was detected in solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and breast cancer, and may be related to malignant development (Arora et al., 2021; Cheng et al., 2021; Kim et al., 2019; Kim et al., 2020; Sekine et al., 2020; Wang et al., 2019).”
BackgroundColorectal Cancer and Purinergic Signalling: An Overview
Roliano, G. G., Azambuja, J. H., Brunetto, V., Butterfield, H. E., Kalil, A. N., & Braganhol, E. (2022) · Cancers · doi:10.3390/cancers14194887 · Cited by 26
Lawton, M. L., Inge, M. M., Blum, B. C., Smith-Mahoney, E. L., Bolzan, D., Lin, W., McConney, C., Porter, J., Moore, J., Youssef, A., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002943 · Cited by 27
“This receptor is a part of the vascular endothelial growth factor receptor (VEGFR) family, specifically bound and activated by VEGF-A, which is often secreted by tumors into the micro-environment and drives TOX-dependent T-cell exhaustion [93].”
Metadata
- Authors
- Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., Kwon, M., Kim, J. H., Lee, A. J., Nam, S. K., Bae, S.-J., Lee, S. B., Shin, S. J., Park, S. H., Ahn, J. B., Jung, I., Lee, K. Y., Park, S.-H., Kim, H., Min, B. S., & Shin, E.-C.
- Affiliations
- Korea Advanced Institute of Science and Technology (KR)
- Yonsei University (KR)
- Corresponding author
- Kim, Chang Gon
- Jang, Mi
- Kim, Hoguen
- Min, Byung Soh
- Shin, Eui-Cheol
- ORCID
- Kim, Chang Gon
- Jang, Mi
- Kim, Youngun
- Leem, Galam
- Kim, Kyung Hwan
- Lee, Hoyoung
- Kim, Tae-Shin
- Choi, Seong Jin
- Kim, Hyung-Don
- Han, Ji Won
- Kwon, Minsuk
- Kim, Jong Hoon
- Lee, Andrew J.
- Nam, Su Kyung
- Bae, Seok-Joo
- Lee, Sat Byol
- Shin, Sang Joon
- Park, Sung Ho
- Ahn, Joong Bae
- Jung, Inkyung
- Lee, Kang Young
- Park, Su-Hyung
- Kim, Hoguen
- Min, Byung Soh
- Shin, Eui-Cheol
- Venue
- Science Immunology
- Published
- 2019-11
- Volume
- 4
- Issue
- 41
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2989029645
- Cited by
- 245
- References
- 67
- Citations by year
- 2026: 29 · 2025: 25 · 2024: 45 · 2023: 32 · 2022: 46 · 2021: 43 · 2020: 24 · 2019: 1
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Ministry of Science and ICT (NRF-2018M3A9D3079498)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- VEGF-A, TOX transcription factor, T cell exhaustion, anti-PD-1 resistance, microsatellite stable colorectal cancer, immune checkpoint blockade, tumor-infiltrating T cells, antitumor immunity
- MeSH terms
- Animals, High Mobility Group Proteins, Humans, Mice, Inbred C57BL, T-Lymphocytes, Colorectal Neoplasms, Homeodomain Proteins, Microsatellite Repeats, Caco-2 Cells, Vascular Endothelial Growth Factor A, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.